Locally Advanced Rectal Cancer – Current Treatment Insights Report – 2025

  • Published Date : January 17, 2025
  • Updated On : August 27, 2025
  • Pages : 51

Locally Advanced Rectal Cancer Current Treatment Insights

Thelansis’s “Locally Advanced Rectal Cancer Current Treatment Insights Report – 2025″ describes the current treatment and management in Locally Advanced Rectal Cancer. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted.

Locally Advanced Rectal Cancer Overview

Locally advanced rectal cancer refers to tumors that have deeply penetrated the rectal wall (beyond the muscularis propria) and may include regional lymph node involvement or invasion of nearby pelvic structures, classified as Stage II or Stage III disease without distant spread. This condition presents a significant therapeutic challenge due to the tumor’s close anatomical relationship to vital pelvic organs and the resulting high risk of locoregional recurrence. Symptoms can include rectal bleeding, changes in bowel habits, pelvic pain, or tenesmus, requiring comprehensive staging via colonoscopy, biopsy, and high-resolution pelvic MRI. Multidisciplinary management typically begins with neoadjuvant chemoradiotherapy, which is designed to shrink and downstage the tumor, maximizing the chance of a curative Total Mesorectal Excision (TME)—the gold-standard surgery to remove the rectum and its surrounding lymphatic tissue.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician specialty(ies) involved in the diagnosis and treatment of patients:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

  • Patient characteristics/patient segments
  • Patient diagnosis criteria
  • Patient shares for current therapies
  • Line of therapy analysis
  • Treatment sequencing
  • Patient journey
  • Compliance and persistency analysis
  • Polypharmacy
  • Factors impacting physician choice of treatments
  • Drivers and barriers to prescribing key brands/treatments
  • Physician-perceived advantages and disadvantages of current therapies
  • Evolving treatment landscape
  • KOL quotes
 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)

Frequently asked questions